Nasal Adenocarcinoma

Nasal adenocarcinoma is a malignant epithelial neoplasm arising from the glandular epithelium of the nasal cavity or paranasal sinuses. It is the most common primary intranasal tumor in dogs and the second most common in cats, accounting for approximately 30-50% of canine nasal tumors and 20-30% of feline nasal tumors. These tumors are locally aggressive, with a high propensity for invasion into adjacent bony structures, the cribriform plate, and the brain. Metastasis to regional lymph nodes or distant sites (lungs, bones) is uncommon at presentation but can occur in advanced stages. The tumor typically arises from the lateral nasal glands, septal glands, or Bowman's glands, and histologically may present as acinar, papillary, solid, or mixed patterns. Clinical staging is essential for treatment planning and prognosis, with the World Health Organization (WHO) TNM classification system commonly used.

The exact etiology of nasal adenocarcinoma is largely unknown, but several risk factors have been implicated. Chronic inflammation of the nasal mucosa, such as that caused by chronic rhinitis, may predispose to neoplastic transformation. Exposure to environmental carcinogens, including tobacco smoke, industrial pollutants, and certain chemicals (e.g., formaldehyde, wood dust), has been suggested in epidemiological studies. In dogs, dolichocephalic breeds (e.g., Collies, Greyhounds) have a higher incidence, possibly due to increased nasal surface area and prolonged contact with inhaled carcinogens. In cats, exposure to environmental tobacco smoke has been associated with an increased risk of nasal tumors, including adenocarcinoma. Genetic mutations, such as activation of oncogenes (e.g., RAS) or inactivation of tumor suppressor genes (e.g., p53), have been identified in some cases, but specific molecular drivers are not well characterized. Viral etiologies have not been confirmed, although feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) have been investigated but not causally linked.

Nasal adenocarcinoma primarily affects older animals, with a median age of 10 years in dogs and 12 years in cats. There is no strong sex predilection, though some studies suggest a slight male predominance in dogs. Breed predispositions in dogs include dolichocephalic breeds such as Collies, Shetland Sheepdogs, Greyhounds, and German Shepherds, while brachycephalic breeds are less commonly affected. In cats, domestic shorthair and longhair breeds are most commonly diagnosed, but no specific breed predisposition has been identified. The incidence of nasal tumors in dogs is estimated at 1-2% of all neoplasms, with adenocarcinoma being the most common histotype. In cats, nasal lymphoma is more common than adenocarcinoma, but adenocarcinoma remains a significant differential. Geographic variation may reflect environmental exposures, but no clear seasonal pattern exists.

Nasal adenocarcinoma originates from the glandular epithelium of the nasal mucosa. The neoplastic cells proliferate locally, forming a mass that progressively obstructs the nasal passages. As the tumor grows, it invades adjacent structures, including the turbinates, nasal septum, and paranasal sinuses. Erosion of the cribriform plate allows intracranial extension, leading to neurological signs. The tumor is typically highly vascular, and local invasion causes destruction of the nasal architecture, leading to hemorrhage and secondary bacterial infections. The release of growth factors and cytokines promotes angiogenesis and local tissue remodeling. Metastasis is uncommon but can occur via lymphatic or hematogenous routes, most frequently to the lungs, regional lymph nodes, and occasionally bones. The tumor's local aggressiveness is the primary cause of morbidity and mortality, with most animals euthanized due to progressive clinical signs and poor quality of life.

Predisposing factors for nasal adenocarcinoma include age (older animals), breed (dolichocephalic dogs), and chronic exposure to environmental carcinogens such as tobacco smoke, industrial pollutants, and certain chemicals. Chronic nasal inflammation or infection may also increase risk. In cats, exposure to environmental tobacco smoke has been identified as a significant risk factor. Genetic predisposition is suggested by breed-specific incidence, but specific genetic markers have not been identified. Immunosuppression, either due to concurrent disease or medication, may also play a role in tumor development. Additionally, prolonged inhalation of irritants or allergens may contribute to mucosal damage and neoplastic transformation.

Clinical signs of nasal adenocarcinoma are often insidious and progressive, with a median duration of 3-6 months before diagnosis. Early signs include unilateral or bilateral serous to mucoid nasal discharge, intermittent epistaxis, sneezing, and stertor (noisy breathing). As the tumor enlarges, signs become more severe and may include facial deformity (swelling over the nasal bridge or maxilla), epiphora (excessive tearing) due to nasolacrimal duct obstruction, exophthalmos (if orbital invasion occurs), and open-mouth breathing. Neurological signs, such as seizures, circling, behavioral changes, or ataxia, may develop if the tumor extends through the cribriform plate into the brain. Anorexia, weight loss, and lethargy are common in advanced stages. On physical examination, a mass may be visible in the nasal cavity on oral examination, and regional lymph nodes may be enlarged if metastasis has occurred.

Differential diagnoses for nasal adenocarcinoma include: 1) Nasal lymphoma (more common in cats, often bilateral, with less bony lysis on imaging; diagnosis via cytology/histopathology). 2) Other nasal tumors (e.g., squamous cell carcinoma, fibrosarcoma, chondrosarcoma, osteosarcoma, undifferentiated carcinoma) – distinguished by histopathology. 3) Chronic rhinitis (infectious, allergic, or inflammatory) – typically less destructive on imaging, responsive to medical therapy; biopsy may show inflammation. 4) Fungal rhinitis (e.g., Aspergillus spp.) – often causes turbinate destruction and may mimic neoplasia; fungal culture and serology are diagnostic. 5) Nasal foreign body – acute onset, unilateral signs, often resolves after removal. 6) Nasal polyps (more common in cats) – benign, but can cause similar signs; imaging and histopathology differentiate. 7) Oronasal fistula – associated with dental disease, visible on oral exam. 8) Trauma – history of injury, imaging may show fracture or hematoma. 9) Autoimmune diseases (e.g., lymphoplasmacytic rhinitis) – chronic inflammation without mass effect. 10) Parasitic rhinitis (e.g., Linguatula serrata) – rare, diagnosed by identification of parasites or eggs.

The diagnostic approach for suspected nasal adenocarcinoma begins with a thorough history and physical examination, including oral examination and palpation of facial bones. Baseline blood work (CBC, serum biochemistry, urinalysis) and thoracic radiographs are recommended to assess for metastasis and concurrent disease. Advanced imaging, preferably computed tomography (CT), is the gold standard for evaluating the extent of the tumor, bony lysis, and intracranial extension. Magnetic resonance imaging (MRI) may be used if brain involvement is suspected. Rhinoscopy allows direct visualization of the mass and collection of biopsy samples. Biopsy is essential for histopathological confirmation and grading. Fine-needle aspiration of regional lymph nodes is recommended to assess for metastasis. If neurological signs are present, cerebrospinal fluid analysis and brain imaging may be indicated. Staging according to the WHO TNM system (T: tumor size and extent, N: lymph node involvement, M: distant metastasis) helps guide treatment and prognosis.

Complete blood count (CBC) may reveal mild anemia due to chronic disease or blood loss from epistaxis. Leukocytosis may be present if secondary bacterial infection occurs. Serum biochemistry is often unremarkable, but elevations in liver enzymes may be seen if metastasis to the liver is present. Urinalysis is typically normal. Specific biomarkers for nasal adenocarcinoma are not available, but inflammatory markers such as C-reactive protein (CRP) may be elevated. Serology for fungal diseases (e.g., Aspergillus) may be negative, helping to rule out fungal rhinitis. Cytological evaluation of nasal discharge may show neoplastic cells, but is not definitive. Histopathology of biopsy samples is the gold standard for diagnosis, with immunohistochemistry (e.g., cytokeratin positivity) confirming epithelial origin.

Radiography of the skull (open-mouth ventrodorsal and lateral views) may show soft tissue opacity within the nasal cavity, loss of turbinate detail, and bony lysis of the nasal bones or maxilla. However, radiography is less sensitive than CT for detecting early lesions and assessing intracranial extension. Computed tomography (CT) is the preferred imaging modality, providing detailed three-dimensional assessment of the tumor extent, bone destruction, and involvement of the cribriform plate. CT findings typically include a contrast-enhancing mass within the nasal cavity, with variable degrees of turbinate destruction and extension into the frontal sinuses or orbit. Magnetic resonance imaging (MRI) is superior for evaluating soft tissue involvement and brain invasion. Thoracic radiographs or CT are recommended to screen for pulmonary metastasis. Ultrasonography is not typically used for nasal tumors, but may be helpful for evaluating regional lymph nodes.

Cytology of fine-needle aspirates from the nasal mass may show clusters of epithelial cells with anisocytosis, anisokaryosis, and prominent nucleoli, but is often nondiagnostic due to necrosis or inflammation. Histopathology of biopsy samples is essential for definitive diagnosis. On histology, nasal adenocarcinoma is characterized by invasive growth of glandular epithelial cells forming acinar, tubular, papillary, or solid patterns. Cells may be cuboidal to columnar, with variable nuclear atypia and mitotic activity. Desmoplasia (fibrous stroma) is common. Special stains, such as mucicarmine or periodic acid-Schiff (PAS), may highlight mucin production. Immunohistochemistry for cytokeratin (AE1/AE3) is positive, while vimentin may be positive in poorly differentiated tumors. Grading (well, moderately, poorly differentiated) may have prognostic significance, with poorly differentiated tumors associated with a worse prognosis.

Treatment of nasal adenocarcinoma is primarily aimed at local tumor control. The standard of care is radiation therapy, either alone or in combination with surgery. Stereotactic radiation therapy (SRT) or intensity-modulated radiation therapy (IMRT) are preferred to deliver high doses to the tumor while sparing normal tissues. A common protocol is 10-18 fractions of 3-4 Gy per fraction, with total doses of 40-54 Gy. Surgery (debulking via dorsal rhinotomy or ventral rhinotomy) may be performed, but is rarely curative due to the invasive nature of the tumor. Chemotherapy (e.g., carboplatin, cisplatin, doxorubicin) has been used as an adjunct, but its efficacy is limited. Palliative care includes management of nasal discharge with saline nebulization, antibiotics for secondary infections, and anti-inflammatory doses of corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q24h) to reduce peritumoral edema. Analgesics (e.g., tramadol 2-5 mg/kg PO q8-12h, gabapentin 5-10 mg/kg PO q8-12h) may be needed for pain. Nutritional support is important if anorexia develops. In advanced cases with brain involvement, euthanasia may be considered due to poor prognosis.

The prognosis for nasal adenocarcinoma is guarded to poor. Without treatment, median survival time (MST) is approximately 3-5 months. With radiation therapy, MST improves to 12-18 months, with 1-year survival rates of 60-70% and 2-year survival rates of 30-40%. Factors associated with a worse prognosis include advanced tumor stage (T3 or T4), involvement of the cribriform plate, presence of neurological signs, and high histologic grade. Metastasis at diagnosis is rare but carries a grave prognosis. Response to treatment, as assessed by improvement in clinical signs and imaging, is also prognostic. Dogs that achieve complete remission have longer survival times. Cats may have a slightly better prognosis, with MST of 12-24 months after radiation therapy. Recurrence is common, and long-term control is challenging.

Follow-up for nasal adenocarcinoma involves regular re-evaluations every 1-3 months for the first year after treatment, then every 3-6 months thereafter. Each visit should include a physical examination, assessment of clinical signs (nasal discharge, sneezing, facial deformity), and thoracic radiographs to screen for metastasis. Repeat CT or MRI is recommended at 3-6 months post-treatment to assess tumor response and detect recurrence. Serial blood work (CBC, biochemistry) may be performed to monitor for treatment-related toxicity. If the patient is on corticosteroids, dose adjustments should be made based on clinical response. Owners should be educated on signs of tumor progression, such as worsening nasal discharge, epistaxis, or neurological signs, and prompt veterinary evaluation is advised. Quality of life assessments are important, and palliative care should be adjusted as needed.

Pearls: 1) CT is essential for accurate staging and treatment planning; radiography underestimates tumor extent. 2) Biopsy is mandatory for definitive diagnosis; cytology alone is often inconclusive. 3) Radiation therapy is the most effective treatment; early referral to a veterinary oncologist is recommended. 4) Neurological signs indicate cribriform plate involvement and a poor prognosis; consider brain imaging. 5) Nasal discharge in an older dog or cat should always raise suspicion for neoplasia, especially if unilateral or associated with facial deformity. Pitfalls: 1) Delaying advanced imaging due to cost or availability can lead to undertreatment. 2) Treating for chronic rhinitis without biopsy may delay diagnosis. 3) Underestimating the tumor's invasiveness on radiographs may lead to incomplete surgical resection. 4) Failing to screen for metastasis, especially to the lungs, can miss advanced disease. 5) Using corticosteroids alone as primary therapy provides only temporary relief and does not alter the disease course.

There are no specific chemotherapeutic protocols that are highly effective for nasal adenocarcinoma, but the following agents have been used: 1) Carboplatin: 300 mg/m² IV q3-4 weeks, up to 4-6 cycles. 2) Cisplatin: 60-70 mg/m² IV q3-4 weeks (requires saline diuresis and antiemetics). 3) Doxorubicin: 30 mg/m² IV q3 weeks (dogs), 1 mg/kg IV q3 weeks (cats) – monitor for cardiotoxicity. 4) Nonsteroidal anti-inflammatory drugs (NSAIDs) such as piroxicam (0.3 mg/kg PO q24h) may have some antitumor activity and provide analgesia. 5) Corticosteroids: prednisone 0.5-1 mg/kg PO q24h, tapering to lowest effective dose, to reduce peritumoral edema and improve clinical signs. 6) Antibiotics (e.g., amoxicillin-clavulanate 12.5-25 mg/kg PO q12h) for secondary bacterial rhinitis. 7) Analgesics: tramadol 2-5 mg/kg PO q8-12h, gabapentin 5-10 mg/kg PO q8-12h, or NSAIDs as above. 8) Antiemetics (e.g., maropitant 1 mg/kg SC q24h) if chemotherapy-induced nausea occurs. Dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered (e.g., NSAIDs with corticosteroids increase GI ulceration risk).

The evidence base for nasal adenocarcinoma is primarily derived from retrospective studies and case series. A landmark study by Adams et al. (1998) reported a median survival time of 14.5 months in dogs with nasal tumors treated with radiation therapy, compared to 3 months without treatment. Another study by Thrall et al. (1993) demonstrated that dogs with nasal tumors treated with radiation therapy had a 1-year survival rate of 60%. More recent studies using IMRT or SRT have shown improved outcomes, with MST of 18-24 months. A study by Fujiwara et al. (2014) found that cats with nasal adenocarcinoma treated with radiation therapy had a MST of 18 months. The role of chemotherapy remains unclear, with some studies showing no significant survival benefit when added to radiation therapy. Consensus guidelines from the Veterinary Society of Radiation Oncology (VSRO) and the American College of Veterinary Radiology (ACVR) recommend radiation therapy as the standard of care. Histologic grade and tumor stage are consistently identified as prognostic factors. Overall, the literature supports aggressive local therapy with radiation, with surgery reserved for debulking or palliation.